Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate [Seeking Alpha]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Seeking Alpha
NTLA's ATTR program is on clinical hold, with no clear timeline for regulatory resolution and persistent platform-level liver risk. Lonvo-z, the HAE program, faces a small target population and entrenched, effective, reversible competitors, limiting its commercial appeal despite operational advantages. Cash burn and potential dilution are ongoing concerns, with a runway estimated into mid-2027, but commercialization prep is likely to escalate spending. Bevan Goldswain/E+ via Getty Images My last look at Intellia Therapeutics ( NTLA ) was in October and followed a Hy's-law-threshold hepatic signal in its Transthyretin Amyloidosis (ATTR) program. I also spent a good amount of time discussing its prospects in hereditary This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 [Seeking Alpha]Seeking Alpha
- Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal [Yahoo! Finance]Yahoo! Finance
- NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.MarketBeat
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 2/3/26 - Form SCHEDULE
- 1/30/26 - Form SCHEDULE
- 1/27/26 - Form 8-K
- NTLA's page on the SEC website